INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Geron Corporation due to alleged violations of federal securities laws, particularly concerning misleading statements about the company's drug Rytelo and its market performance [3][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Geron to contact them, highlighting a deadline of May 12, 2025, to seek the role of lead plaintiff in a federal securities class action [1][6]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [2]. Group 2: Allegations Against Geron - The complaint against Geron alleges that the company and its executives made false and misleading statements regarding their ability to meet market needs and execute their commercial plans, while downplaying risks associated with Rytelo [3]. - Geron reported that Rytelo's growth had flattened, attributing this to seasonality, competition, lack of awareness, and monitoring requirements [4]. Group 3: Stock Price Impact - Following the announcement of Rytelo's diminished growth, Geron's stock price fell from $2.37 per share on February 25, 2025, to $1.61 per share on February 26, 2025, marking a decline of approximately 32.07% in one day [5].